<\/p>\n
Rivamer<\/strong> is an oral capsule from Sun Pharma containing rivastigmine 1.5 mg<\/strong> — a dual acetylcholinesterase + butyrylcholinesterase inhibitor<\/strong> used for the symptomatic treatment of mild-to-moderate Alzheimer's disease<\/strong> AND Parkinson's disease dementia<\/strong> (the only AChE inhibitor licensed for PDD). Slow titration: 1.5 mg twice daily for 2 weeks → 3 mg twice daily for 2 weeks → 4.5 mg twice daily for 2 weeks → 6 mg twice daily maintenance<\/strong>. Always take with food.<\/strong> The transdermal patch (not stocked here) significantly reduces GI side effects and is preferred for patients who cannot tolerate the oral form.<\/p>\n<\/div>\n \ud83d\udce6 Minden rendel\u00e9st fedez a \u00dajrak\u00fcld\u00e9si Garancia<\/strong><\/a> \u2014 ha a csomagod nem \u00e9rkezik meg 20 munkanapon bel\u00fcl, \u00fajrak\u00fcldj\u00fck.<\/p>\n Generikus gy\u00f3gyszereink WHO-GMP min\u0151s\u00edt\u00e9s\u0171 gy\u00e1rt\u00f3kt\u00f3l sz\u00e1rmaznak, \u00e9s diszkr\u00e9t, egyszer\u0171 csomagol\u00e1sban sz\u00e1ll\u00edtjuk \u0151ket vil\u00e1gszerte \u2014 a csomagon nem szerepel a gy\u00f3gyszer neve. A k\u00e1rty\u00e1s fizet\u00e9sek egy szab\u00e1lyozott feldolgoz\u00f3n kereszt\u00fcl t\u00f6rt\u00e9nnek (a sz\u00e1mlale\u00edr\u00e1sok egy szab\u00e1lyozott k\u00e1rtyafizet\u00e9si feldolgoz\u00f3t tartalmaznak \u2014 soha nem \u201cMedsBase\u201d vagy b\u00e1rmilyen gy\u00f3gyszer neve). Kriptovalut\u00e1t \u00e9s SEPA banki \u00e1tutal\u00e1st is elfogadunk. Minden rendel\u00e9st a Reshipment Assurance Policy biztos\u00edt\u00e9k fedez.<\/p>\n Rivamer is an oral capsule from Sun Pharma containing rivastigmine tartrate 1.5 mg<\/strong>. Rivastigmine is a pseudo-irreversible dual cholinesterase inhibitor<\/strong> — it inhibits both acetylcholinesterase (AChE)<\/strong> \u00e9s butyrylcholinesterase (BuChE)<\/strong>. The dual mechanism distinguishes it from donepezil and galantamine, which only inhibit AChE.<\/p>\n Rivamer from Sun Pharma is a 1.5 mg rivastigmine capsule — the starting dose for the 6–8 week titration in mild-to-moderate Alzheimer's and Parkinson's disease dementia. Titrate to the maintenance 12 mg\/day dose. Always take with food to minimise the GI side effects that are characteristic of oral rivastigmine. Rivastigmine is the only cholinesterase inhibitor with a licensed indication for Parkinson's disease dementia<\/strong> in addition to mild-to-moderate Alzheimer's. The dual ACh + BuChE inhibition may matter more in PDD because BuChE activity is relatively preserved in PD compared with Alzheimer's.<\/p>\n Both Alzheimer's disease and Parkinson's disease dementia involve cholinergic neuron loss. Rivastigmine raises synaptic acetylcholine through dual enzymatic inhibition:<\/p>\n Onset of cognitive benefit: visible at 6\u201312 h\u00e9ten<\/strong> on the maintenance 9–12 mg\/day dose; peak at 6 months.<\/p>\n Rivamer is nem<\/strong> indicated for: severe Alzheimer's disease (only donepezil is licensed at this stage), mild cognitive impairment, frontotemporal dementia (worsens behavioural symptoms), or as a cognitive enhancer in healthy adults.<\/p>\n Rivamer comes at 1,5 mg<\/strong> capsules. The 6–8 week titration is mandatory — rivastigmine has the most aggressive GI profile of all AChE inhibitors when given orally.<\/p>\n Standard 6–8 week titration:<\/strong><\/p>\n Common (highest GI burden of all oral AChE inhibitors):<\/strong><\/p>\n Kevesebb gyakori, de fontos:<\/strong><\/p>\n Rare but seek medical attention:<\/strong><\/p>\nMi\u00e9rt rendelj a MedsBase-r\u00f3l<\/h3>\n
What Is Rivamer?<\/h2>\n
How Does Rivamer Work?<\/h2>\n
\n
Felhaszn\u00e1l\u00e1s \u00e9s indik\u00e1ci\u00f3k<\/h2>\n
\n
Rivamer Dosage and How to Take — SLOW TITRATION<\/h2>\n
\n
How to Take Rivamer Properly<\/h3>\n
\n
Side Effects of Rivamer<\/h2>\n
\n
\n
\n
Figyelmeztet\u00e9sek \u00e9s el\u0151vigy\u00e1zatoss\u00e1g<\/h2>\n
\n
Contraindications — Who Should NOT Take Rivamer<\/h2>\n
\n
Gy\u00f3gyszerk\u00f6lcs\u00f6nhat\u00e1sok<\/h2>\n